Publications by authors named "Paul G Foster"
Article Synopsis
- TIGIT is an inhibitory receptor that competes with CD226 on immune cells, and targeting it may improve anti-tumor immunity, especially in exhausted CD8+ T cells and regulatory T cells.
- Combining different types of anti-TIGIT antibodies (Fc-enabled and Fc-silent) with another treatment showed varied effects on tumors: Fc-enabled antibodies reduced regulatory T cell numbers, while Fc-silent antibodies did not deplete these cells but enhanced the activity of tumor-specific CD8+ T cells.
- The study highlights that Fc-silent anti-TIGIT antibodies can drive antitumor responses by activating exhausted T cells without affecting regulatory T cells, indicating their potential for cancer therapy.
Importance: The humanized monoclonal antibody atezolizumab targets programmed death-ligand 1 and has demonstrated durable single-agent activity in a subset of metastatic triple-negative breast cancers. To extend the observed activity, combinatorial approaches are being tested with standard cytotoxic chemotherapies known to induce immunogenic tumor cell death.
Objective: To examine the safety, tolerability, and preliminary clinical activity of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancers.
Background: Cabozantinib (XL184), an orally bioavailable inhibitor of vascular endothelial growth factor receptor 2 and MET, was assessed in a cohort of ovarian carcinoma patients as part of a phase 2 randomised discontinuation trial (RDT) with cohorts from nine different tumour types.
Patients And Methods: Patients received 100-mg cabozantinib daily. Those with stable disease (SD) per Response Evaluation Criteria in Solid Tumors at week 12 were randomised to cabozantinib or placebo.
The crystal structure of E. coli Fmu, determined at 1.65 A resolution for the apoenzyme and 2.
View Article and Find Full Text PDF